Evidence map›Paper›PMID 42601609›Full record

SynthesisBMC infectious diseases2026

Incidence of neonatal sepsis among HIV exposed neonates of mothers on integrase strand transfer inhibitors in sub-Saharan Africa: a systematic review and meta-analysis.

Pebalo Francis Pebolo, Felix Bongomin, Bethan Morgan, Ivaan Pitua, Ritah Nantale, Venice Omona, Joseph Ngonzi, Davidson H Hamer

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pebalo Francis PeboloDepartment of Obstetric and Gynecology, Faculty of Medicine, Gulu University, Gulu, Uganda. pebolo.pebalo@gu.ac.ug.
Felix BongominDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.
Bethan MorganManchester University NHS Foundation Trust, Manchester, UK.
Ivaan PituaSchool of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Ritah NantaleDepartment of Public Health, Busitema University, Mbale, Uganda.
Venice OmonaDepartment of Paediatrics, St Mary's Hospital Lacor, Gulu, Uganda.
Joseph NgonziDepartment of Obstetrics and Gynaecology, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Davidson H HamerDepartment of Global Health, Boston University School of Public Health, Boston, MA, USA.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
FIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

introductionHuman immunodeficiency virus (HIV)-exposed infants face elevated risks of neonatal sepsis, influenced by maternal antiretroviral therapy (ART) regimens. Dolutegravir (DTG), a widely used integrase transfer inhibitor (INSTI), and the preferred first line drugs for management of HIV in pregnancy, has shown potential adverse effects such as hyperglycaemia, which may impact neonatal outcomes including risk of neonatal sepsis. We estimated the pooled incidence of neonatal sepsis among neonates exposed to INSTIs in utero compared to non-INSTIs-based ART regimens. METHODS AND ANALYSIS: A systematic review and meta-analysis were conducted following written as per the PRISMA guidelines. Databases including PubMed/MEDLINE, Embase, Cochrane Library, CINAHL, Global Health and Global Index Medicus were searched for studies published between January 2013 and September 2025. Eligible studies included clinical trials and cohort studies comparing INSTI-based ART regimens with non-INSTI regimens among pregnant women living with HIV. Data were extracted using Covidence software, Cochrane risk of bias (RoB) and Newcastle-Ottawa Scale (NOS) were used to assessed for quality of randomised clinical trials and observational studies, respectively. The certainty of the evidence was assessed using the Grading, Recommendation, Assessment, Development and Evaluation (GRADE) framework.

resultsA total of 714 studies were identified and screened based on their titles and abstracts, of which 63 articles underwent full-text review. Ultimately, four studies, comprising 7,636 participants, met the predefined eligibility criteria and were included in the analysis. The pooled odds ratio (OR) for neonatal sepsis among infants exposed to INSTIs was 0.44 (95% confidence interval [CI]: 0.15-1.30, p = 0.137). The test for subgroup difference was not significant (p = 0.358): the pooled OR for dolutegravir was 0.27 (95% CI 0.06-1.23, p = 0.090) and for the single raltegravir study was 0.73 (95% CI 0.16-3.30, p = 0.681).

conclusionINSTI-based ART was not associated with a significant difference in neonatal sepsis risk compared with non-INSTI regimens. However, the low number of events limited the precision of the estimates, highlighting the need for further research. REGISTRATION: This review has been registered with the PROSPERO at https://www.crd.york.ac.uk/PROSPERO/view/CRD420251178411 , registration number CRD420251178411.

Indexed as

HIV InfectionsHIV Integrase InhibitorsNeonatal SepsisPregnancy Complications, InfectiousAfrica South of the SaharaDolutegravirFemaleHeterocyclic Compounds, 3-RingHumansIncidenceInfant, NewbornOxazinesPiperazinesPregnancyPyridonesDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesAntiretroviral therapyDolutegravirHIV-exposed infantsNewborn infectionRaltegravir

Identifiers

PMID42601609
PMCPMC13474507

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.